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Purpose: To evaluate the eﬀects of eslicarbazepine acetate (ESL) on lipid metabolism and to determine whether
reduced statin exposure during ESL therapy has clinical consequences.
Subjects and methods: We conducted a post-hoc analysis of pooled data for serum lipids (laboratory values) from
three phase III, multicenter, randomized, double-blind, placebo-controlled trials of adjunctive ESL therapy (400,
800, or 1200 mg once daily) in patients with treatment-refractory partial-onset seizures. Changes from baseline
in serum lipid levels were analyzed according to use of statins and/or enzyme-inducing antiepileptic drugs
(EIAEDs) during the baseline period.
Key ﬁndings: In total, 426 and 1021 placebo- and ESL-treated patients, respectively, were included in the analysis. With regard to the changes from baseline in serum concentrations, there were statistically signiﬁcant
diﬀerences between the placebo and ESL 1200 mg QD groups, for both total cholesterol (TC) and high-density
lipoprotein cholesterol (HDL-C), but the eﬀect sizes were small (+4.1 mg/dL and +1.8 mg/dL, respectively). A
small but signiﬁcant diﬀerence in low-density lipoprotein cholesterol (LDL-C; −5.0 mg/dL) was observed between the ESL 400 mg QD group and the placebo group. In patients not taking a concomitant EIAED, there were
no changes with ESL 400 mg QD, but modest and statistically signiﬁcant increases in cholesterol fractions (TC,
LDL-C and HDL-C) with ESL 800 mg QD (< 6 mg/dL) and ESL 1200 mg QD (< 10 mg/dL). ESL had no consistent
eﬀect on lipids in patients taking a concomitant EIAED. In patients taking statins during baseline, there were no
clinically relevant changes in serum lipids during use of ESL, although the subgroups were small.
Signiﬁcance: These results suggest that ESL does not appear to have clinically signiﬁcant eﬀects on serum lipids,
nor does the pharmacokinetic interaction between ESL and statins have an impact on serum lipid concentrations.

1. Introduction
Mounting evidence has linked the use of enzyme-inducing

antiepileptic drugs (EIAEDs), particularly carbamazepine and phenytoin, with elevations in serum lipids (Brämswig et al., 2003; Chuang
et al., 2012; Mintzer et al., 2009; LoPinto-Khoury and Mintzer, 2010).

⁎

Corresponding author.
E-mail addresses: Scott.Mintzer@jeﬀerson.edu (S. Mintzer), wechsler5@me.com (R.T. Wechsler), joanne.rogin@mpls-clinic.com (J.B. Rogin), barry.gidal@wisc.edu (B.E. Gidal),
Matthias.Schwab@ikp-stuttgart.de (M. Schwab), Elinor.Ben-Menachem@neuro.gu.se (E. Ben-Menachem), MCARRENO@clinic.cat (M. Carreño), Psoares.silva@bial.com (P.S. da Silva),
Joana.Moreira@bial.com (J. Moreira), Yan.Li@sunovion.com (Y. Li), David.Blum@sunovion.com (D. Blum), Todd.Grinnell@sunovion.com (T. Grinnell).
https://doi.org/10.1016/j.eplepsyres.2018.02.001
Received 4 August 2017; Received in revised form 19 January 2018; Accepted 7 February 2018
Available online 09 February 2018
0920-1211/ © 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).

Epilepsy Research 141 (2018) 83–89

S. Mintzer et al.

conducted as part of the New Drug Application submitted to the Food
and Drug Administration for ESL, data from study –303 were not considered by the regulator, nor have they been included in this analysis.

These drugs appear to have inherent lipid-elevating properties, likely
due to induction of the CYP450 enzymes of the cholesterol synthesis
pathway (Gibbons, 2002; Mintzer and Mattson, 2009).
In patients receiving treatment for hypercholesterolemia, there is
concern that EIAEDs may exacerbate their condition by inducing metabolism of HMG-CoA reductase inhibitors (‘statins’). Statins are the
most commonly used lipid-lowering agents, and most are broken down
by hepatic enzymes. Carbamazepine has been speciﬁcally shown to
reduce the area under the curve for simvastatin concentrations by 75%
(Ucar et al., 2004), while phenytoin has demonstrated a similar interaction with atorvastatin (Bullman et al., 2011). It is possible that other
eﬀects of EIAEDs may contribute to the reduced bioavailability of statins reported during concomitant administration (Gidal et al., 2017).
However, none of these studies evaluated the eﬀect of AEDs on serum
lipid levels.
The antiepileptic drug (AED) eslicarbazepine acetate (ESL), approved in the U.S. and Europe as once-daily treatment for focal seizures,
underwent several Phase II and Phase III trials in both epilepsy and nonepilepsy populations on the road to regulatory approval. As part of the
safety evaluation, these trials included monitoring of a number of serologic parameters, including serum lipids. Some of the patients in these
trials were being treated concomitantly with statins; this is relevant
because use of ESL has been shown to lead to signiﬁcant reductions in
plasma exposure to both simvastatin (Bialer and Soares-da-Silva, 2012;
Falcão et al., 2013) and rosuvastatin (Gidal et al., 2017). As and its
active entity are CYP3A4 substrates, this interaction is most likely due
to CYP3A4 induction by ESL (Bialer and Soares-da-Silva, 2012; Falcão
et al., 2013). The latter interaction is more curious, as rosuvastatin
undergoes minimal enzymatic metabolism, and the nature of the ESLrosuvastatin interaction is not well understood at present (Gidal et al.,
2017). Moreover, the clinical impact of reduced statin exposure, while
assumed, has never been directly demonstrated in any study of any
AED.
Here we report aggregated lipid data from clinical trials of ESL in
patients with epilepsy. Our investigation had two goals: ﬁrst to ascertain whether ESL has any direct eﬀect on lipid metabolism; and second
to determine whether reduced statin exposure during ESL therapy has
clinical consequences, by measuring the endpoint of statin treatment −
serum lipid levels – in statin users taking ESL.

2.2. Serum lipid measurements and data analysis
In all trials, blood samples were taken for assessment of standard
blood chemistry, hematology and coagulation parameters. Data were
analyzed according to whether or not patients were taking statins
and/or EIAEDs during the 8-week baseline period. For the purpose of
the analysis, baseline statin use was used as an indicator of concomitant
use, on the assumption that changes in statin use were unlikely to have
occurred during the relatively brief duration of the trials. As use of
AEDs during baseline was speciﬁed to continue throughout the trials,
baseline EIAED use should be equivalent to concomitant use. The means
and standard deviations of the changes in serum lipid levels from
baseline to the ﬁnal visit (end of study, or early termination visit) were
calculated. Baseline was deﬁned as the last visit prior to the ﬁrst dose of
study medication. Lipid measurements included total cholesterol (TC),
low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), and triglycerides (TRIG). Non-fasting measurements were obtained, as recommended by the Joint Consensus
Initiative of the European Atherosclerosis Society and European
Federation of Clinical Chemistry and Laboratory Medicine
(Nordestgaard et al., 2016). A generalized linear model was used to
determine the overall eﬀect of treatment on changes from baseline in
serum lipid concentration (eﬀect size: each ESL dose group versus
placebo). A separate generalized linear model was used to evaluate the
eﬀect of treatment in patients taking or not taking EIAEDs during the
baseline period and a third model was used to assess eﬀect size in patients taking or not taking an EIAED and/or a statin during the baseline
period.
EIAEDs used by one or more patients during the baseline period
included carbamazepine, phenytoin, and phenobarbital. The statins
used by patients during the trial included simvastatin, atorvastatin,
pravastatin, rosuvastatin, lovastatin and ﬂuvastatin.
Data are presented for the safety population (all patients who received at least one dose of study medication).
3. Results

2. Methods
3.1. Baseline characteristics and exposure to ESL
2.1. Studies
The safety population comprised 426 and 1021 placebo- and ESLtreated patients, respectively (Table 1). The mean daily dose for ESLtreated patients was 785 mg, and the median duration of ESL exposure
was 98 days.
Patient demographics were well balanced across the treatment
groups, with approximately equal numbers of males and females, and
mean age approximately 38 years in all groups (median 37–38 years;
Table 1). The majority of patients (97% of both the placebo and total
ESL groups) were taking 1–2 AEDs during the baseline period; the
most commonly used AEDs during baseline were carbamazepine,
lamotrigine, valproic acid, and levetiracetam. Approximately 60% of
patients were receiving an EIAED during the baseline period (placebo
group, 60%; ESL groups, 61%). During the baseline, statins were used
by 18 patients taking placebo (4%) and 46 taking ESL (5%); statin use
is shown in Table 2; some patients received > 1 drug.

This is a post-hoc analysis of pooled lipid data from three Phase III
epilepsy trials (2093-301, 2093-302 and 2093-304 [ClinicalTrials.gov
identiﬁers: NCT00957684, NCT00957684 and NCT00988429, respectively]. Each was a multicenter, randomized, double-blind, placebocontrolled study in patients with treatment-refractory partial-onset
seizures. Individual details of each trial have been reported (BenMenachem et al., 2010; Elger et al., 2009; Sperling et al., 2015); brieﬂy,
the pooled population from these clinical trials comprised patients aged
16 or older, taking between 1 and 3 concomitant AEDs. All trials had, as
part of the protocol, the requirement that concomitant AEDs be maintained at stable doses throughout the double-blind portion of the trial.
Each study had an 8-week baseline period, followed by a 2-week
double-blind titration period and a 12-week double-blind, ﬁxed-dose
maintenance period. At the end of the baseline period, patients were
randomized to one of 3 or 4 treatment arms (placebo and ESL doses of
400, 800, or 1200 mg QD, depending on the study).
A fourth multicenter, randomized, double-blind, placebo-controlled
phase III study (2093-303 [NCT00957372]) has also been conducted.
The ﬁndings of this study (Gil-Nagel et al., 2009) were consistent with
those of studies −301, −302 and −304, but the study was deemed not
to be in full accordance with Good Clinical Practice (GCP) standards.
Consequently, in the analysis of safety and eﬀectiveness of ESL

3.2. Serum lipid concentrations
Fig. 1 shows mean changes in lipid levels from baseline to end of
study/early-termination visit, in patients who were taking or were not
taking statins during baseline. Eﬀect sizes (diﬀerences in the change
from baseline in serum lipid concentrations between the treatment
groups and the placebo group) and related levels of statistical
84
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Table 1
Patient demographics and baseline characteristics (safety population).
ESL

Age (years),
mean (SD)
median (range)
Males, n (%)
Race/Ethnicity, n (%)
Caucasian
Black
Asian
Hispanic
Other
BMI, kg/m2,
mean (SD)
Region, n (%)
Eastern Europe
Latin America
Western Europe
North America
Rest of the world
Concomitant AEDs taken at baseline
Mean (SD)
n (%)
1
2
≥3
AEDs taken at baseline, n (%)
Carbamazepine
Lamotrigine
Levetiracetam
Valproic acid
Enzyme-inducing AEDs at baseline, n (%)
Statin users at baseline, n (%)

Placebo
n = 426

400 mg QD
n = 196

800 mg QD
n = 415

1200 mg QD
n = 410

Total
n = 1021

37.8 (12.4)a

37.5 (11.3)

38.7 (12.3)

37.7 (11.8)

38.1 (11.9)

37 (16–68)
212 (50)

37 (18–70)
89 (45)

38 (16–75)
214 (52)

37 (16–69)
201 (49)

504 (49)

331 (78)
14 (3)
46 (11)
7 (2)
28 (7)
25.3 (5.3)b

187 (95)
2 (1)
2 (1)
1 (1)
4 (2)
24.6 (4.7)

326 (79)
14 (3)
41 (10)
5 (1)
29 (7)
25.4 (5.1)c

317 (77)
17 (4)
44 (11)
6 (1)
26 (6)
25.7 (5.7)d

830 (81)
33 (3)
87 (9)
12 (1)
59 (6)
25.4 (5.3)e

132 (31)
90 (21)
58 (14)
81 (19)
65 (15)

95
53
33
0
15

(8)

126 (30)
94 (23)
52 (13)
78 (19)
65 (16)

131 (32)
87 (21)
59 (14)
77 (19)
56 (14)

352
234
144
155
136

1.8 (0.5)a

1.7 (0.5)

1.8 (0.5)f

1.7 (0.5)g

1.7 (0.5)h

116 (27)a
297 (70)a
12 (3)a

63 (32)
127 (65)
6 (3)

107 (26)f
292 (71)f
13 (3)f

117 (29)g
280 (68)g
12 (3)g

287 (28)h
699 (69)h
31 (3)h

198 (46)
108 (25)
89 (21)
95 (22)
256 (60)
18 (4)

116 (59)
46 (23)
23 (12)
37 (19)
133 (68)
2 (1)

204 (49)
93 (22)
80 (19)
95 (23)
245 (59)
22 (5)

204 (50)
105 (26)
73 (18)
86 (21)
246 (60)
22 (5)

524 (51)
244 (24)
176 (17)
218 (21)
624 (61)
46 (5)

(48)
(27)
(17)

(34)
(23)
(14)
(15)
(13)

AEDs, antiepileptic drugs; BMI, Body Mass Index; ESL, eslicarbazepine acetate; SD, standard deviation.
a
n = 425.
b
n = 424.
c
n = 414.
d
n = 408.
e
n = 1018.
f
n = 412.
g
n = 409.
h
n = 1017.

serum lipid concentration between the placebo group and the ESL
groups were very modest (< 10 mg/dL); the diﬀerences were non-signiﬁcant at ESL 800 mg QD and signiﬁcant for TC and HDL-C at 1200 mg
QD, but the magnitude of eﬀect was very small (approximately 4 mg/dL
and 2 mg/dL, respectively). At 400 mg QD, the diﬀerence in LDL-C was
signiﬁcant, but again the eﬀect size was small (≤5 mg/dl).

Table 2
Statins used by patients enrolled in the trials.

Simvastatin
Atorvastatin
Pravastatin
Rosuvastatin
Lovastatin
Fluvastatin

Placebo

Total ESLa

n = 426

n = 1021

n

%

n

%

6
9
2
4
1
0

1.4
2.1
0.5
0.9
0.2
0

23
12
6
4
3
2

2.3
1.2
0.6
0.4
0.3
0.2

3.4. Impact of EIAED use
Since it is known that EIAEDs have a substantial eﬀect on serum
lipids, we evaluated changes from baseline in serum lipid concentrations during ESL therapy (separately for patients who were and were
not taking EIAEDs). Fig. 3 summarizes the changes from baseline in
serum lipid concentrations (eﬀect size versus placebo) during ESL
therapy, according to use of EIAEDs. In ESL-treated patients who were
not taking an EIAED during the baseline period, there was an apparent
eﬀect of ESL on cholesterol fractions (TC, LDL-C and HDL-C); for TC and
HDL-C, the eﬀect appeared to be dose-related. No eﬀects were apparent
in the ESL 400 mg QD dose group; signiﬁcant elevations in TC and LDLC (relative to placebo) occurred in the ESL 800 mg QD dose group, and
larger elevations in TC and HDL-C were seen in the ESL 1200 mg QD
dose group, along with a similarly-sized elevation for LDL-C, with the
diﬀerences being signiﬁcant for all three measures. The eﬀect sizes
were quite modest even at the highest dose (3–5 mg/dL for the

The data are the number and percent patients taking each drug (some were taking more
than one drug).
ESL, eslicarbazepine acetate.
a
All dose groups combined.

signiﬁcance are shown in Figs. 2–4.
3.3. Overall eﬀect of ESL on serum lipids
The eﬀect of ESL on serum lipids in the overall population is shown
in Fig. 2. As can be seen, diﬀerences in the change from baseline in
85

Epilepsy Research 141 (2018) 83–89

S. Mintzer et al.

Fig. 1. Mean changes in serum lipid levels* in (A) patients not taking statins and (B)
patients taking statins.
The data shown are changes in serum concentration between baseline and end of study/
early-termination visit.
Numbers represent numbers of patients.
Data are not shown for patients randomized to ESL 800 mg QD who were taking statins
during baseline (n = 2).
a
n = 376; bn = 402; cn = 376; dn = 373.
ESL, eslicarbazepine acetate; HDL-C, high-density lipoprotein cholesterol; LDL-C, lowdensity lipoprotein cholesterol; TC, total cholesterol; TRIG, triglycerides.

Fig. 3. Eﬀect of ESL on changes from baseline in serum lipid concentrations, according to
concomitant (baseline) EIAED use. (A) Patients not taking an EIAED during baseline. (B)
Patients taking an EIAED during baseline.
The data are eﬀect sizes (ESL minus placebo) for the change in serum lipid concentration
between baseline and end of study/early-termination visit, without correction for concomitant (baseline) statin use.
*p ≤0.05; **p ≤ 0.01; ***p ≤ 0.001 versus placebo (Wald test).
a
n = 160; bn = 163; cn = 235; dn = 234.
ESL, eslicarbazepine acetate; EIAEDs, enzyme-inducing antiepileptic drugs; HDL-C, highdensity lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total
cholesterol; TRIG, triglycerides.

cholesterol fractions, 9 mg/dL for TC). TRIG was not signiﬁcantly affected by ESL at any dose. In patients who were taking an EIAED, no
consistent eﬀect of ESL on lipids was apparent.

3.5. Statin-treated patients
Finally, we examined the impact of ESL on lipids in patients who
were being treated with a statin. Again, the data are summarized according to use of EIAEDs, as this class of drugs is known to have substantial pharmacokinetic interactions with at least some statins, and
this could confound the impact of ESL on the eﬀects of the statins. Fig. 4
summarizes the eﬀect sizes for change from baseline in serum lipid
concentrations, according to use of EIAEDs and statins. Note that data
for the ESL 400 mg QD group are not reported for patients taking or not
taking an EIAED during baseline, as only one patient in each subgroup
who received this dose were taking a statin. Among statin users who
were not taking an EIAED, there were no signiﬁcant changes in lipids
during treatment with ESL, except for higher HDL-C in the 800 mg/day
group, although the total number of subjects was small (ESL 400 mg,
n = 1; ESL 800 mg, n = 9; ESL 1200 mg, n = 10; placebo: n = 10)
(Fig. 4A, left panel). In a similarly-sized group who took both an EIAED
and a statin (ESL 400 mg, n = 1; ESL 800 mg, n = 13; ESL 1200 mg,
n = 11; placebo, n = 8), again there was no signiﬁcant eﬀect of ESL on
serum lipids (Fig. 4B, left panel). Among patients who were taking
neither a statin nor an EIAED, there was a modest increase in TC, LDL-C

Fig. 2. Eﬀect of ESL on changes from baseline in serum lipid concentrations.
The data are eﬀect sizes (ESL minus placebo) for the change in serum lipid concentration
between baseline and end of study/early-termination visit, without correction for concomitant (baseline) use of statins and EIAEDs.
Placebo, n = 420–421.
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 versus placebo (Wald test).
a
n = 397; bn = 398; cn = 394.
ESL, eslicarbazepine acetate; EIAEDs, enzyme-inducing antiepileptic drugs; HDL-C, highdensity lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total
cholesterol; TRIG, triglycerides.

86
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Fig. 4. Eﬀect of ESL on changes from baseline in serum lipid levels according to concomitant (baseline) use of EIAEDs and statins. (A) Patients not taking an EIAED during baseline. (B)
Patients taking an EIAED during baseline.
The data are eﬀect sizes (ESL minus placebo) for the change in serum lipid concentration between baseline and end of study/early-termination visit.
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 versus placebo (Wald test).
a
n = 150; bn = 154; cn = 222; dn = 223.
ESL, eslicarbazepine acetate; EIAEDs, enzyme-inducing antiepileptic drugs; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol;
TRIG, triglycerides.

results in this subgroup yield our second ﬁnding, which is that ESL has
only a very modest eﬀect on serum lipids. In contrast to carbamazepine,
which appears to increase TC by approximately 25 mg/dL, regardless of
dose (Mintzer et al., 2009), the eﬀect of ESL on TC was dose-dependent;
even the highest dose led to an increase of only 9 mg/dL. The diﬀerence
was statistically signiﬁcant, suggesting that it may have been a drug
eﬀect, although the post-hoc nature of the analysis and the fact that
there was no adjustment for multiplicity means that all conclusions
must be tempered with caution; the magnitude of the diﬀerence,
however, was well below the threshold that most clinicians would
consider to be clinically signiﬁcant, and in the moderate-dose group the
diﬀerence was smaller still. This suggests that ESL may not be associated with clinically meaningful hyperlipidemia.
Third, and most intriguing, are the ﬁndings in statin-treated patients. Like carbamazepine (Ucar et al., 2004), ESL has also been shown
to substantially reduce exposure to simvastatin, presumably by inducing the metabolizing enzymes (Falcão et al., 2013). It would be expected that other statins metabolized by the CYP450 system (such as

and HDL-C in the ESL 1200 mg group (Fig. 4A, right panel), similar to
the eﬀect described in the preceding paragraph (among patients who
were not taking an EIAED, but may or may not have been taking a
statin).
4. Discussion
Our examination of the eﬀect of ESL on lipids in epilepsy patients
yielded 3 main ﬁndings. First, ESL had no eﬀect on serum lipid concentrations in patients who were being treated with concomitant
EIAEDs. This makes sense insofar as AED-induced lipid alterations are
believed to be due to eﬀects on CYP450 enzymes (Mintzer and Mattson,
2009), and ESL may be a less potent inducer of CYP450 enzymes than
drugs such as carbamazepine and phenytoin. This would imply that in
patients taking an EIAED, many such enzymes are in an “induced” state,
so adding ESL does not lead to any further enzyme induction.
To evaluate any direct eﬀects of ESL on lipid levels, it is necessary to
investigate patients who are not being treated with an EIAED. The
87
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period cannot be excluded as potential confounding factors. We also did
not account for the various statins and the spectrum of dosing of these
agents in our analyses, as this would have resulted in even smaller
subgroups that would not have been amenable to analysis. Directed
interaction studies in patients not taking EIAEDs, and with individual
statins at speciﬁc dosing levels, would provide the best test of whether
or not use of ESL leads to changes in serum lipid concentrations. Finally, it is important to bear in mind that the current analyses are posthoc analyses, and as such are subject to a number of potential biases.
Directed prospective studies of ESL–statin interactions would provide
higher-level evidence to answer these questions, although, clearly, any
such studies should use clinical outcome measures (e.g. lipid levels)
rather than pharmacokinetic measures.

lovastatin and atorvastatin) should be similarly aﬀected. In turn, it
would be expected that the marked reductions in statin exposure engendered by the AEDs would lead to reductions in the eﬃcacy of the
statins, resulting in elevations in serum cholesterol. Yet the current data
show that use of ESL in patients taking statins did not lead to meaningful changes in serum lipid concentrations. This suggests that standard drug interaction studies, which evaluate statin exposure by measuring AUC and pharmacodynamic parameters (other than lipid
concentrations) may not truly reﬂect the clinical function of the drug in
this context. The reasons for this are unclear, although the evidence for
a pharmacokinetic interaction between ESL and the statins was derived
from studies conducted in relatively small numbers of healthy volunteers (less than 30) who took ESL followed by a single dose of the
diﬀerent statins (Bialer and Soares-da-Silva, 2012; Gidal et al., 2017).
The scenarios examined by the current analyses reﬂect chronic dosing,
and therefore resemble more closely the concomitant use of these
medications in day-to-day clinical practice, which may be more informative for clinicians. Another potential explanation could be that
ESL might reduce plasma exposure to some statins, not by inducing
their hepatic metabolism, but by increasing their uptake from the
plasma compartment into hepatocytes by membrane transporters
(Gidal et al., 2017). Since hepatocytes are the ultimate site of action of
statins in reducing plasma lipid levels, this speculative interaction may
not lead to alterations in cholesterol-lowering function, even with an
apparent reduction in plasma statin levels. However, the exact eﬀect of
eslicarbazepine on these transporters is not currently understood, and
further research will be required to determine the underlying mechanisms. Further work is likewise needed to ascertain whether pharmacokinetic interactions between carbamazepine and statins, and between phenytoin and statins, are functionally meaningful.
The eﬀect of ESL on serum lipids appears similar to that of the related drug oxcarbazepine, which also produces modest, clinically-insigniﬁcant increases in serum lipids (Garouﬁ et al., 2014; Kim et al.,
2013). As mentioned previously, the original compound in the class,
carbamazepine, causes substantial elevations in serum lipids, lipoprotein(a), and C-reactive protein (Mintzer et al., 2009). It has been demonstrated that switching patients from carbamazepine to oxcarbazepine causes serum lipids to decline (Isojärvi et al., 1994), and one might
expect that switching from carbamazepine to ESL would have a similar
eﬀect, although this remains to be demonstrated directly.
The major limitation of the study is the limited sample size of the
subgroups. While the overall cohort was substantial in size, with over
1000 drug-treated subjects, dividing the cohort by ESL dose, by use of
EIAEDs, and by use of statins produced subgroups of as few as 8–10
patients. More focused study of some of these subgroups (particularly
patients taking statins and not taking EIAEDs) is warranted in order to
conﬁrm our ﬁndings. In fact, among the statin-treated patients, there
was no indication of any clear or consistent dose-dependent and clinically signiﬁcant eﬀects of ESL on serum lipid concentrations.
Another limitation is the relatively short observation period of 12
weeks. It remains uncertain whether longer durations of treatment with
ESL might have a diﬀerent impact on serum lipids; this could be larger
(if the time to maximal drug eﬀect is longer than the study duration) or
smaller (if an early eﬀect is subsequently reversed by a homeostatic
mechanism). However, neither of these possibilities is likely, as the
eﬀects of AEDs on the CYP450 system are rapid, and changes in serum
lipids occur within 6 weeks of initiation of AED therapy and remain
stable over the longer term (Mintzer et al., 2016). With regard to other
potential limitations, the analyses are exploratory in nature, so no adjustment for multiplicity was performed. Instead, we evaluated individual comparisons to determine whether they ﬁtted a plausible
pattern. Another limitation is that the analyses used a proxy indicator of
concomitant statin use. Although it is unlikely that patients’ use of
statins would have changed during the 14-week trials, the information
on use of statins was for the baseline period only. Consequently,
changes in statin use in individual patients during the double-blind

5. Conclusions
In summary, we ﬁnd that adjunctive treatment with ESL led to
modest eﬀects on serum lipids that were unlikely to be clinically signiﬁcant. Our data also suggest that pharmacokinetic interactions between ESL and various statins may not have clinically signiﬁcant
pharmacodynamic eﬀects. While further study is required, our ﬁndings
suggest that ESL might be used safely and without complications in
patients who are receiving statin therapy for hyperlipidemia.
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